Unicycive Therapeutics reports preliminary Q2 2026 cash balance of $61.4M

Unicycive Therapeutics, Inc.

Ending cash balance of approximately $61.4 million as of June 30, 2026.
Preliminary, unaudited results for the second quarter ended June 30, 2026.
No other financial details or comparisons provided in the filing.

item 8.01

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-074678

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.